This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
What’s more, your highest revenue service lines are likely already facing stiff competition from all angles. . For these reasons and more, it’s imperative to identify your unique selling propositions, review them, and revise them regularly to remain competitive. . So, how can your brand stay competitive? The answer is twofold.
The Association of the British Pharmaceutical Industry (ABPI) has drawn attention to a new report , which has emphasised the importance of UK advanced manufacturing requiring a long-term strategy to ensure its continued success. Article: Are we globally prepared for the next pandemic?
to address the potential competitive harm Amgen’s $27.8 Consolidation in the pharmaceutical industry has given companies the power and incentive to engage in exclusionary rebating practices, which can lead to sky-rocketing prices on essential medications,” stated Henry Liu, Director of the FTC’s Bureau of Competition.
Drastic steps need to be taken if the UK is to reverse a steep decline in medicines manufacturing in recent years, according to a cross-industry coalition. Since 2010, the UK has fallen from 4th to 98th place in overall trade balance in pharmaceuticals, due to fierce global competition, according to the MMIP. It’s not all bad news.
According to the European Federation of Pharmaceutical Industries and Associations (EFPIA), more than 600 essential medicines are at risk if a proposed restriction on the use of fluorinated substances, per- and polyfluoroalkyl substances (PFAS) across pharmaceutical manufacturing in the EEA, is implemented.
To address these issues, companies should adopt more advanced production strategies such as continuous flow chemistry, as they can shorten manufacturing processes, increase productivity and throughput. These insights help to drive highly efficient manufacturing processes, ensuring competitive product delivery on time and within budget.
While maintaining a healthy manufacturing industry for production of ‘high tech’ pharmaceuticals, Europe has stepped away from manufacturing essential medicines and active pharmaceutical ingredients (APIs) due to unrelenting price pressures and is now heavily reliant on the import of these critical ingredients.
The pharmaceutical industry is becoming increasingly conscious of emissions and the importance of sustainable manufacturing. 1 Every major pharmaceutical manufacturer in the UK and Ireland is investing in making their operations and supply chains more environmentally friendly.
On 10 March, the National Health Service Blood and Transplant (NHSBT) opened a new Clinical Biotechnology Centre (CBC) with the aim of improving the UK’s ability to develop and manufacture cell and gene therapies. This is important due to the UK’s currently limited short-scale manufacturing capacity.
In the interview, conducted at CPHI Barcelona, Krishna Venkatesh, Global Head, Sterile Manufacturing Operations at Dr Reddy’s Laboratories explores industry’s growing focus on achieving end-to-end connectivity, as well as the potential of automation and track and trace solutions. KV : We have seen two specific elements.
Conducted last month, survey respondents expect that tariffs will bring: A significant number of biotechs (94 percent) anticipate a surge in manufacturing costs if tariffs are put in place on import trade from the EU, thereby decreasing access to affordable medicines.
o find out about the current trends in cell and gene therapy manufacturing, EPR spoke to Cell and Gene Therapy Catapult (CGT Catapult)’s Chief Manufacturing Officer, Stephen Ward, and Chief Business Officer, Jeanette Evans. Licensing of the manufacturing suites is expected in early 2024. So now we have a really nice blend.”
Ready to start leveraging QR code technology and stay ahead of your competition? In this blog post, you’ll learn: Why QR codes have made a comeback, When to use them, And, 8 ways to improve the patient experience and drive leads with QR codes. . 8 Ways to Improve the Patient Experience & Drive Leads with QR Codes.
Key areas included in the Political Guidelines Increasing competitiveness Harnessing innovation–covering digital, collaboration, strategy and more—was conveyed as a vital component for improving European competitiveness. As such, she noted that the initial priority will be “prosperity and competitiveness.”
Overreliance on automation can lead to complacency and blind trust in technology, leading to potential oversight of critical errors or deviations. Leaders need to lead by example and inspire others to do the same. This proactive approach enhances regulatory compliance, improves operational efficiency and reduces costs.
Advancements in manufacturing technology, plus availability of cost-effective treatment options are also influencing the sector. This can restrict a manufacturer’s capacity to make income. Other molecule types Small molecule API manufacturers are in fierce competition with medicines such as biologics, the report stated.
These two insulin therapies have been off patent for about a decade but have a list price of about $500 for a pack of five injection pens and currently have limited competition from biosimilars. Price reductions of Humalog and Humulin by 70%, Lilly’s two best-selling insulin formulations, will be made in the fourth quarter of this year.
They do not have biosimilar or generic competition available in the market. Over the next few weeks, manufacturers will submit a range of clinical, marketing, sales, pricing, and patient data, and then meet with CMS to discuss submissions later this fall. They do not qualify for any exemption (e.g.,
Pharmaceutical Technology has listed the leading payers in pharma based on its intel, insights, and decades-long experience in the sector. Competitive intelligence studies. The post Leading payers in the pharmaceutical industry appeared first on Pharmaceutical Technology. Concept evaluation testing. Marketing trend analysis.
Influencing factors identified in the report include higher competition, competitive pricing and inflation rate, technological advancements and evolving regulatory guidelines. Enhanced interconnectivity of equipment and technologies has also put demand on manufacturing operations. These factors have led to industry 4.0
Sales reps in the manufacturing industry face unique challenges. Competition is fierce, buyers often come to the table with preconceived notions—notions that must be adjusted to make sales—and prices continue to plummet in an attempt to win business. A strong manufacturing sales training program can help. The result?
2 Modified CDs have higher solubility and even substitution with hydrophobic side groups leads to improved solubility. When a pH range is defined, a buffer is normally used to stabilise the pH in this range – if possible, this buffer should be selected to have no interaction with the CD, as this would form a competitive complexation.
Results from CPhI’s 2022 Pharma Index survey , announced at this year’s CPhI Frankfurt, showed pharma confidence in growth , innovation and manufacturing quality has reached record highs, promising positive prospects for the industry in 2023 and beyond. Competitiveness. Key countries. Finished Dosage. Knowledge of professionals.
To be a superpower globally, the UK life sciences sector must not only discover and develop medicines of the future domestically, but also manufacture a significant share in the country too, according to a new report from the Medicines Manufacturing Industry Partnership (MMIP). It provides almost 45 percent of the £36.9
UKRI highlighted that overall, these investments will “enhance the UK’s global competitiveness by supporting research and innovation that leads to new and disruptive biomanufacturing processes across the UK.” Curious about sustainability in pharmaceutical manufacturing and the supply chain?
Manufacturing sales is anything but simple. You just need to implement an effective manufacturing sales strategy to meet your company’s revenue goals. What Is Manufacturing Sales? Put simply, manufacturing sales is what happens when a manufacturer sells its own products. We can help you with that!
To prepare for the second order effects of the IRA, one important step that we recommend for manufacturers is to clearly articulate and outline the remaining uncertainties regarding how the IRA will be implemented by CMS and identify scenarios most likely to impact their products. Acceptance and Consideration of Manufacturer Evidence.
Based on the agreement, Teva stated that by leading the regulatory processes and commercialisation in planned regions, the company will facilitate broader access of the biosimilar to eligible patients. Therefore, there has been “increased competition and price pressure, driving the growth of the biosimilar market”.
tariffstargeting imports from key manufacturing hubs like China, Mexico, and Canadais set to introduce new challenges that will reshape the landscape of medical device sales and manufacturing in 2025. based manufacturers relying on imported parts. A core objective of these tariffs is to bring more manufacturing back to the U.S.,
The drive to make the UK a ‘scientific powerhouse’ was central to the government’s announcement closing out 2022 , which appointed five industry experts to lead on the sectors most vital to UK’s future innovation. For biotech to achieve our societal goals, we need to build up the foundational systems that support modern science.
This article outlines how developers can utilize sustainability initiatives to boost revenue, reduce costs, and advance innovation, ensuring a strategic, long-term, and more sustainable position in today’s competitive landscape. Implementing sustainable processes requires investigating every operational layer.
At Roche at the time, his job was to lead a task force which was given the objective of planning a strategy to preserve and protect the companies billion-dollar originator biologics franchises as well as build a plan which would counter the introduction and use of biosimilars. Look, competition is healthy.
In this final instalment of IQVIA EMEA Thought Leadership’s Nine for 2023 three-part series, focusing on issues that will change the direction of healthcare and the pharmaceutical industry this year, three key competitive issues for pharmaceutical companies in 2023 are assessed. Medicines manufacturing is energy intensive.
By harnessing the power of 3D technology, medical device manufacturers can mitigate risks, reduce costs, and ultimately bring safer, more effective products to market faster. These iterative processes can delay product launches and increase overall expenses, making it difficult to stay competitive in a fast-paced market.
Commercial dose companies form a critical component of the pharmaceutical manufacturing industry’s value chain. The dose form manufacturing follows API manufacturing to produce the final dosage form (FDF such as tablets and injectables. Discover the leading commercial dose companies in contract marketing.
The proposed autonomous process analytical technology (PAT) platform comprises of a micro sequential injection (µSI) process analyser and automatic assay preparation platform (A2P2) for use in the laboratory as an off-line analytical system and on the manufacturing floor.
The US Food and Drug Administration (FDA)’s Center for Drug Evaluation and Research (CDER) through the Office of Pharmaceutical Quality in 2021 embarked on an initiative to develop a framework for establishing a pharmaceutical manufacturing site quality rating system, the Quality management maturity (QMM) programme.
For hundreds of years, we have found myriad uses for microbial enzymes in manufacturing – from food, drink, and household products to a range of industrial applications. The enzymes must be manufactured under cGMP conditions – completely free of animal-derived ingredients.”. That is a key competitive advantage,” says Laursen. “We
According to GlobalData’s report, Coronavirus Disease 2019 (Covid-19) Analyst Consensus Sales Analysis and Forecast, H1 2022 , Comirnaty is the leading prophylactic Covid-19 vaccine and recorded sales of $41.3bn in 2021. AbbVie reported a 22.7% Bristol Myers Squibb (BMS) documented a 9.1%
Nordic healthcare providers are leading the momentum in enhancing ESG considerations. We examine the regional developments that will provide a competitive edge to pharma manufacturers.
During your team discussions on Data and SWOT analysis it may have become clear that your lead management system is terrible. A lot of good leads are not being followed up on. Sending a lead out to a sales person is not “lead follow-up” unless it requires the sales person to regularly report the status of that lead.
In June, generic drug manufacturing giants wrote to the EU to request help with rising costs so that their products remain viable. It also stresses that some pharma manufacturers are at risk of having gas rationed or being unable to continue manufacturing due to high prices.
However, we expect drugs without strong therapeutic alternatives to have an advantage in negotiations, while drugs in highly competitive classes will be negotiating from a weaker position. In the near term, manufacturers may need to reconsider price increase strategy given inflation penalties for Medicare beneficiaries.
We organize all of the trending information in your field so you don't have to. Join 8,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content